Answers are grounded in this paper and cite their sources.
The publication in 2017 of guidelines on the assessment and management of hypertension by the American Heart Association/American College of Cardiology (AHA/ACG) redefined hypertension and reappraised the previously established blood pressure (BP) targets [1]. Stage 1 hypertension is now defined as a systolic BP (SBP) of 130–139 mmHg or a diastolic BP (DBP) of 80–89 mmHg. For those with hypertension and known cardiovascular disease or 10-year cardiovascular event risk >10%, BP is now recommended to be targeted at a lower level of <130/80 mmHg [1]. Reclassification of hypertension in the 2017 AHA/ACG guidelines was based on clinical trial evidence showing that intensive therapy targeting a lower SBP of <120 mmHg (versus a standard SBP target <140 mmHg) is translated into improvement in ‘hard’ clinical outcomes [2]. Intensive BP lowering was shown to offer cardiovascular risk reduction in non-diabetic patients with chronic kidney disease (CKD) [3]. Publications in Nephrology Dialysis Transplantation (NDT) in 2017 in the field of hypertension in CKD add some support to these guidelines. In this editorial, we select and discuss the results of five ‘landmark’ studies that offer new insights and provide directions for future research in this important area. Arterial stiffness, a consequence of vascular remodelling with ageing, is commonly recognized as an established predictor of cardiovascular morbidity and mortality [4]. Arterial stiffness mediates its adverse cardiovascular effects by enhancing flow and pressure pulsatility [5, 6]. Exposure of the vulnerable renal microcirculation to high systemic pulsatile pressure in the presence of accelerated arteriosclerosis may promote microvascular damage at the kidney level and hasten renal function decline [4–6]. The longitudinal association of arterial stiffness with the change in estimated glomerular filtration rate (eGFR) was explored in a subanalysis of 629 elderly Icelandic participants in the Age Gene/Environment Susceptibility Reykjavik Study [7]. Arterial stiffness was assessed at baseline by measuring aortic pulse wave velocity (PWV) and augmentation index (AIx) via applanation tonometry. According to baseline characteristics, the mean age of study participants was 74.8 ± 3.7 years, 58% had a history of hypertension, 9.9% had a history of diabetes and 19.6% had an eGFR <60 mL/min/1.73 m2 [7]. When eGFR was used as a continuous variable in analysis, higher baseline aortic PWV was associated with declining eGFR over a mean follow-up of 5.3 years {β = −0.24 mL/min/1.73 m2/year per 1 standard deviation higher baseline aortic PWV [95% confidence interval (CI) −0.40 to −0.08]}. This association remained significant after adjustment for age, gender, height, heart rate and baseline eGFR, but was mitigated after additional adjustment for mean arterial pressure [7]. Higher baseline AIx had no association with the change in eGFR over time. When eGFR was treated as a dichotomous variable in fully adjusted models, higher baseline aortic PWV was independently associated with 53% higher odds for a ≥3 mL/min/1.73 m2 decline in eGFR [odds ratio (OR) 1.53 (95% CI 1.11–2.13)]. Similarly, higher baseline AIx was independently associated with 44% higher odds for a 30% decline in eGFR during follow-up [OR 1.44 (95% CI 1.03–2.00)] [7]. Although the observational study design cannot provide direct cause–effect associations, these findings support the notion that arterial stiffness is an independent predictor of eGFR decline in the elderly. If the relationship is causal, then therapies and interventions that improve arterial stiffness may also offer renal protection. Therapeutic decisions on the management of hypertension are routinely based on office BP recordings obtained on a single visit at the clinic, despite the fact that BP measurements obtained in multiple visits or out-of-office BP monitoring may better detect the presence of target organ damage or provide superior prognostic associations with clinical outcomes [8]. In a prospective cohort of 255 veterans with hypertension and Stages 2–4 CKD, Agarwal [9] evaluated the ability of different BP-monitoring techniques to predict target organ damage as assessed by increasing arterial stiffness over a follow-up of 2–4 years. BP was monitored using three separate approaches: triplicate office BP recordings in a single visit (office-S), triplicate office BP recordings obtained in three separate visits within 1 week (office-M) and 24-h ambulatory BP monitoring. Target organ damage was assessed by measuring aortic PWV with an echo-Doppler technique at baseline and at serial intervals thereafter [9]. At baseline, study participants (overall cohort) had a mean age of 69.4 ± 9.4 years, a mean eGFR of 43.6 ± 15.6 mL/min/1.73 m2 and were receiving therapy with a mean of 3.1 ± 1.4 antihypertensive medications. The change in aortic PWV displayed wide variability within the same subject from one visit to the next, but the net population change in aortic PWV during follow-up did not significantly differ from zero [9]. Although aortic PWV remained practically unchanged, a significant linear increment in SBP was detected over time. Each 10-mmHg increment in office-S SBP was associated with a non-significant −0.51% change in aortic PWV (P = 0.69). In contrast, each 10-mmHg increment in office-M SBP was associated with a significant 4.15% increase in aortic PWV (P = 0.041). With respect to 24-h ambulatory SBP, daytime SBP was superior to nighttime SBP in predicting the increase in aortic stiffness over time [9]. Accordingly, among hypertensives patients with Stages 2–4 CKD, BP recordings obtained in multiple visits and daytime ambulatory BP exhibited strong longitudinal associations with the change in aortic PWV, whereas office BP recorded on a single occasion was unable to predict the growth of target organ damage. Given that the technique of ambulatory BP monitoring is not widely available and is difficult to apply repeatedly in daily clinical practice, therapeutic decisions and the overall management of hypertension should be guided by BP recordings obtained in multiple visits at the clinic. This study tells us that the measurements taken at a single clinic visit are less valuable than those taken over multiple visits, even when the visits are just a week apart. Clinic BP measured after 5 min of seated quite rest at multiple clinic visits—as suggested by the ACC/AHA guidelines—should guide the management of hypertension [1]. Although the failure of the renal sympathetic denervation in patients with treatment-resistant hypertension (SIMPLICITY HTN 3) trial was considered as the termination of sympathetic renal denervation (RDN) [10], subsequent proof-of-concept sham-controlled trials support the safety and efficacy of this intervention for BP lowering in patients with resistant hypertension [11]. It has to be noted, however, that although the above clinical trial evidence has taken the concept of RDN one step forward, principle steps in the mechanism of BP-lowering action of this intervention still remain elusive. A major hurdle in interpreting the results of RDN is the lack of simple measures of whether the renal artery was successfully denervated. Unlike before-and-after angiograms after balloon angioplasty, there are no simple tests or biomarkers to establish whether RDN was successful. The gold standard to measure efferent sympathetic outflow is the record of the peroneal nerve muscle sympathetic nerve activity (MSNA). MSNA measurement is technically demanding and not widely available, but it is a reliable marker of sympathetic outflow. Whereas experimental support that RDN down-regulates sympathetic nerve traffic [12], whether this procedure is similarly effective in humans is unproven. In an incident series of 29 patients with resistant hypertension (defined as office SBP ≥160 mmHg despite the use of three antihypertensive drugs, including a diuretic), Seravalle et al. [13] performed serial microneurographic measurements of MSNA to ascertain the effect of bilateral RDN on sympathetic activity over a 6-month follow-up. Concomitantly with MSNA measurements, triplicate in-lab BP recordings were obtained under standardized conditions and their interrelation with treatment-induced changes in MSNA was explored [13]. Bilateral RDN provoked a significant decrease in MSNA (67.5 ± 13.1 versus 51.3 ± 15.5 burst/100 heartbeats, P < 0.01) during follow-up. This effect on MSNA was accompanied by a parallel drop of 21 mmHg in standardized in-lab SBP and a reduction of 9 mmHg in DBP. Time-integrated analysis showed that the proportional change in MSNA was directly and closely associated with the change in standardized in-lab SBP (β = 0.61, P < 0.001) and DBP (β = 0.37, P < 0.01) [13]. These results offer mechanistic insights on the BP-lowering action of RDN: (i) RDN effectively down-regulates sympathetic nerve traffic in resistant hypertension and (ii) down-regulation of sympathetic overactivity is, perhaps, the main mechanistic explanation for the BP-lowering response to RDN. Additional research efforts are warranted to elucidate whether the BP-lowering effect of RDN is clinically meaningful. To be so, BP lowering should be long-lasting and should be accompanied by regression of target organ damage and improvement in ‘hard’ clinical outcomes. Clinical measures—instead of the measurement of MSNA—to assess the efficacy of RDN would be a welcome addition to our toolbox. The Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) trial was an open-label, multicentre trial in which 806 patients with atherosclerotic renovascular disease (ARVD) were randomly assigned to revascularization in addition to medical therapy or medical therapy alone for a median follow-up of 34 months [14]. Revascularization had no benefit over medical care in retarding the progression of renal damage, which was the primary outcome of the ASTRAL trial [14]. The efficacy of revascularization versus medical therapy on cardiac structure and function was explored in a prespecified cardiac magnetic resonance (CMR) substudy enrolling 51 patients with ARVD from six ASTRAL centres [15]. Of the 51 patients enrolled, 44 completed this substudy and a full dataset was available for 40 participants. Consistent with the main results of the ASTRAL trial, revascularization was not superior to medical therapy in improving cardiac structure and function, as assessed with CMR imaging at baseline and after 12 months of follow-up [15]. In particular, there were no differences between the revascularization and medical therapy groups in the change from baseline of CMR-assessed left ventricular (LV) mass (−6.3 versus −5.4 g, P = 0.8), LV ejection fraction (−0.8 versus −1.5%, P = 0.7), LV end-systolic volume (0.3 versus −2.1 mL, P = 0.7) and LV end-diastolic volume (−5.8 versus −1.9 ml, P = 0.4) [15]. It could be argued that the above negative results are attributable to the small sample size, which may not have provided sufficient statistical power. The investigators acknowledge that the sample size is a limitation. However, they also note that the between-group differences are clinically small. Such differences would probably remain non-meaningful even in the case of an adequately powered analysis with statistically significant results [15]. We agree. The results of this ASTRAL substudy are clinically relevant because the absence of benefit on cardiac structure and function further dismisses the broad application of renal revascularization as a therapeutic approach for ARVD. Assessment of volume status among adult patients on dialysis is challenging, given that clinical judgement (i.e. presence or absence of pedal oedema) cannot reliably detect volume expansion [16, 17]. Lung ultrasound is a non-invasive and radiation-free technique that aids in the detection of subclinical lung congestion with high sensitivity and reproducibility among adult end-stage renal disease (ESRD) patients on haemodialysis or peritoneal dialysis [18, 19]. In a prospective observational study incorporating data from 123 lung ultrasound measurements performed in eight children with acute kidney injury (AKI) requiring dialysis and 15 children with ESRD on dialysis, Allinovi et al. [20] explored the diagnostic accuracy of this technique in the paediatric dialysis population. Among children with AKI, the lung ultrasound B-line score decreased from 5 (range 0–22) at AKI onset to 1.5 (range 0–4) at recovery [20]. The reduction in B-line score was paralleled with improvement in volume overload quantified by body weight measurements from 7.2% excess (range –1.9–15.2) to 0% excess. The lung ultrasound B-line score and volume overload judged via body weight measurements were strongly and linearly associated in children with AKI (r = 0.83) and ESRD (r = 0.61). The lung ultrasound B-line score was also able to detect acute (real-time) changes in body weight from pre- to post-haemodialysis [20]. Taken together, these preliminary but provocative results suggest a potential role of lung ultrasound as a simple and reliable approach to detect subclinical volume expansion among children on dialysis. Larger studies and interventional trials are needed to confirm these findings. Prof Rajiv Agarwal is supported by a grant from the National Institute of Health (NIH) with number (NIH 5 R01 HL126903-02) and a grant from the US Department of Veterans Affairs Merit Review (5I01CX000829-04).
No takes yet. Share an insight, caveat, or question.
Georgianos et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: